May 17, 2023 02:23 PM EDTUpdated May 17, 09:35 PM

Intercept's NASH hopeful gets preliminary thumbs down in FDA briefing docs

Nicole DeFeudis

Editor

The FDA has once again raised safety concerns around the use of Intercept’s obeticholic acid in NASH, concluding in briefing documents ahead of an upcoming …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Intercept's NASH hopeful gets preliminary thumbs down in FDA briefing docs

Nicole DeFeudis

Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

In­ter­cep­t's NASH hope­ful gets pre­lim­i­nary thumbs down in FDA brief­ing docs

Editor

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Intercept's NASH hopeful gets preliminary thumbs down in FDA briefing docs